ATNX stock forecast
Our latest prediction for Athenex, Inc.'s stock price was made on the Sept. 24, 2020 when the stock price was at 11.81$.
In the short term (2weeks), ATNX's stock price should underperform the market by -0.18%. During that period the price should oscillate between -10.20% and +11.10%.
In the medium term (3months), ATNX's stock price should underperform the market by -3.50%. During that period the price should oscillate between -37.51% and +23.73%.Get email alerts
Create a solid portfolio with ATNX
About Athenex, Inc.
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
At the moment the company generates 141M USD in revenues.
On its last earning announcement, the company reported a loss of -1.44$ per share.
The book value per share is 1.87$
Three months stock forecastSept. 24, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|